Tuberculosis (TB) is one of those Step 1 organisms that keeps showing up because it connects everything: immunology (Th1 response), pathology (caseating granulomas), pharmacology (RIPE therapy), and classic imaging/vignette clues. If you can explain why TB behaves the way it does, most questions become pattern recognition.
Where Mycobacterium tuberculosis Fits (and Why It’s Weird)
Mycobacterium tuberculosis is an acid-fast, obligate aerobe that causes chronic pulmonary infection with potential for systemic dissemination.
Key structural features (high-yield)
- Acid-fast bacillus (AFB)
- Due to a mycolic acid–rich cell wall (waxy cell envelope)
- Slow-growing
- Explains prolonged culture times and why therapy must be long
- Cord factor (trehalose dimycolate)
- Virulence factor; promotes serpentine cording and impairs neutrophil migration
- Sulfatides
- Help inhibit phagolysosome fusion (survival inside macrophages)
First Aid cross-reference: Microbiology → Mycobacteria (M. tuberculosis: acid-fast properties, cord factor, sulfatides); Immunology → Th1/IFN-γ/macrophage activation; Pharmacology → anti-TB drugs (RIPE, adverse effects).
Transmission & Epidemiology: How Patients Get It
Transmission
- Airborne spread via droplet nuclei (coughing, sneezing, singing)
- Highest risk with close, prolonged indoor exposure (prisons, shelters, households)
Classic risk factors tested on USMLE
- HIV/AIDS (especially low CD4)
- Recent immigration from endemic areas
- Homelessness / incarceration
- Malnutrition, alcoholism
- Diabetes
- Silicosis (silica impairs macrophage function → TB risk)
- TNF-α inhibitors (e.g., infliximab) → reactivation risk
Pathophysiology: The Step 1 “Story” You Must Know
TB is primarily a disease of cell-mediated immunity—the symptoms and tissue damage are driven by the host response.
Step-by-step immune mechanism
- Inhaled bacilli reach alveoli → macrophages phagocytose them.
- TB prevents phagolysosome fusion (sulfatides), survives intracellularly.
- Macrophages present antigen → Th1 differentiation.
- Th1 cells secrete IFN-γ → activates macrophages to kill intracellular organisms.
- Activated macrophages and T cells form granulomas to wall off infection.
Cytokines you’re expected to name
- IL-12: from macrophages → drives Th1 differentiation
- IFN-γ: from Th1 cells → activates macrophages
- TNF-α: helps maintain granuloma integrity (block it → reactivation)
Caseating granulomas (why they matter)
- Caseous necrosis = “cheesy,” acellular debris in the center
- Seen in TB and certain fungi (Step likes asking the differential)
High-yield association:
- Defect in IL-12 receptor or IFN-γ receptor → severe disseminated mycobacterial infections (also poor control of some intracellular pathogens)
Primary vs Reactivation TB (A Favorite Test Split)
| Feature | Primary TB | Reactivation (Secondary) TB |
|---|---|---|
| Typical patient | Children, new exposure | Adults, immunocompromised |
| Location | Lower part of upper lobe or upper part of lower lobe (mid-lung zones) | Apices (high O₂ tension) |
| Lesion | Ghon focus; with hilar nodes = Ghon complex | Cavitary lesions common |
| Spread potential | Can disseminate early | Can disseminate (miliary) if uncontrolled |
Why apical disease?
TB is an obligate aerobe, and the apices have higher oxygen tension.
Clinical Presentation: What the Vignette Looks Like
Pulmonary TB (classic symptoms)
- Chronic cough (often >3 weeks)
- Hemoptysis
- Fever, night sweats
- Weight loss, anorexia
- Fatigue, malaise
Extrapulmonary TB (Step loves these)
- Pott disease (vertebral osteomyelitis)
- Back pain; vertebral collapse; can cause spinal cord compression
- Scrofula
- TB cervical lymphadenitis
- TB meningitis
- Subacute meningitis; basilar involvement; cranial nerve palsies
- Genitourinary TB
- Sterile pyuria, dysuria
- Miliary TB (hematogenous dissemination)
- “Millet seed” lesions throughout lungs; systemic symptoms; can involve liver, spleen, bone marrow
Diagnosis: Tests, What They Mean, and Common Traps
Screening for infection (latent vs exposure)
Tuberculin skin test (TST/PPD)
- Delayed-type (Type IV) hypersensitivity reaction measured at 48–72 hours
- Requires intact cell-mediated immunity → false negatives can occur in:
- HIV, chronic steroids, very young/old
- Overwhelming TB disease
- Recent infection (window period)
Interferon-gamma release assays (IGRAs)
- Measures IFN-γ release in response to TB antigens
- Not affected by BCG vaccination (major Step point)
- Often preferred in BCG-vaccinated patients or those unlikely to return for reading
High-yield: BCG vaccine
- Live attenuated Mycobacterium bovis
- Can cause false-positive PPD, but IGRA stays specific for TB infection
Diagnosing active TB disease
No single test is perfect—Step questions often combine clinical + lab + imaging.
Sputum studies
- AFB smear (Ziehl-Neelsen or auramine-rhodamine)
- Fast, but not fully sensitive or species-specific
- NAAT/PCR on sputum
- Rapid detection; can identify resistance markers depending on platform
- Culture (Lowenstein-Jensen medium)
- Definitive, but slow (weeks)
Imaging clues
- Reactivation: apical cavitary disease
- Primary: hilar adenopathy (especially in kids) + Ghon complex
- Miliary: diffuse, tiny nodules throughout lung fields
Treatment: RIPE, Duration Logic, and Adverse Effects You Must Memorize
Active TB (standard initial therapy)
RIPE for 2 months, then continuation phase depending on susceptibility:
- Rifampin
- Isoniazid (INH)
- Pyrazinamide
- Ethambutol
Then typically INH + rifampin for an additional 4 months (common total = 6 months) if drug-susceptible pulmonary TB.
The long duration isn’t arbitrary: TB grows slowly and can persist intracellularly and in necrotic lesions—short courses risk relapse/resistance.
Latent TB infection (LTBI)
Common regimens include:
- INH (often 6–9 months)
- Rifampin (shorter courses in some protocols)
- INH + rifapentine weekly for a shorter course (common modern option)
(Exact regimen can vary by guideline; Step tends to focus more on drug toxicities and the concept of treating latent infection to prevent reactivation.)
Anti-TB Drugs: Mechanisms + Toxicities (Step 1 Gold)
| Drug | Mechanism | Major adverse effects | High-yield pearls |
|---|---|---|---|
| Rifampin | Inhibits DNA-dependent RNA polymerase | Hepatotoxicity, orange body fluids, potent CYP450 inducer | Also used for prophylaxis of N. meningitidis, H. influenzae type b |
| INH | Inhibits mycolic acid synthesis | Hepatotoxicity, peripheral neuropathy, drug-induced lupus | Give vitamin B6 (pyridoxine) to prevent neuropathy |
| Pyrazinamide | Prodrug active in acidic environments (phagolysosomes) | Hepatotoxicity, hyperuricemia | Think “Pyrazinamide → Produces uric acid” |
| Ethambutol | Inhibits arabinosyltransferase → ↓ cell wall | Optic neuritis (↓ visual acuity, red-green color blindness) | Monitor vision; used to prevent resistance early |
First Aid cross-reference: Pharmacology → antimycobacterial drugs (mechanisms + toxicities); Microbiology → mycolic acid cell wall.
Drug Resistance & Public Health Concepts
Why combination therapy?
- Prevents selection of resistant mutants due to high bacterial burden and long treatment duration.
MDR-TB and XDR-TB (conceptual)
- MDR-TB: resistant to at least INH and rifampin
- XDR-TB: MDR plus resistance to key second-line drugs
Step questions may not demand the exact definition, but they love the idea that incomplete therapy → resistance.
Airborne precautions (NBME-style hospital question)
- Negative-pressure room
- Provider wears N95 respirator
- Patient wears a surgical mask when transported
High-Yield Associations & “Classic Stem” Clues
What to highlight when reading a vignette
- Chronic cough + night sweats + weight loss
- Hemoptysis or cavitary lung lesion
- Homeless, prison, immigrant, HIV, TNF-α inhibitor use
- Apical disease on imaging
- AFB-positive sputum; granulomas with caseation on pathology
Common “why” questions
- Why granulomas? Th1/IFN-γ macrophage activation walls off intracellular pathogen.
- Why reactivation with TNF inhibitors? Loss of granuloma maintenance → organisms escape containment.
- Why false-negative PPD in HIV? Weak cell-mediated immunity → poor Type IV response.
Rapid Review (What You Should Be Able to Say in 20 Seconds)
- Acid-fast, slow-growing, obligate aerobe with mycolic acids.
- Survives in macrophages by inhibiting phagolysosome fusion.
- Controlled by Th1 response: IL-12 → Th1, IFN-γ → macrophage activation; forms caseating granulomas (TNF-α maintains them).
- Reactivation favors apices and causes cavitary lesions.
- Diagnosis: IGRA (BCG-safe), AFB smear/NAAT/culture, imaging patterns.
- Treatment: RIPE; memorize adverse effects (rifampin orange/CYP inducer; INH neuropathy + B6; PZA hyperuricemia; EMB optic neuritis).